Characteristics and Safety Profile in Patient Received Ixazomib in China: Interim Analysis of a National, Prospective, Non-Interventional Study of Using Ixazomib in Real-World Clinical Practice (INFINITE Study)

伊扎莫布 临时的 中期分析 医学 临床实习 临床试验 家庭医学 医学物理学 重症监护医学 内科学 历史 考古 多发性骨髓瘤 蛋白酶体抑制剂 Carfilzomib公司
作者
Chengcheng Fu,Xin Zhou,Junling Zhuang,Fan Zhou,Yuhua Li,Wen-Ming Chen,Rong Fu,Baijun Fang,Ting Niu,Hao Zhang,Lin Li,Depei Wu
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 12642-12644
标识
DOI:10.1182/blood-2022-165127
摘要

Background: China Food and Drug Administration formally approved the marketing of imported Ixazomib Citrate capsules in China on Apr 25, 2018. Pre-marketing clinical research was conducted restrictively in relapsed refractory multiple myeloma (RRMM) patients (pts) with multiple exclusion criteria and was not a comprehensive reflection of Ixazomib (IXA) real-world pts safety circumstances. Therefore, it is necessary to conduct a prospective post-marketing study to understand the gap between real clinical practice and pre-marketing clinical research. Aim: To report the characteristics and safety profile of IXA in Chinese multiple myeloma pts. We report an interim analysis (IA) of the INFINITE study. Method: INFINITE Study (NCT04328662) is a prospective, non-interventional, single-country study. Pts who have received at least one dose of IXA-based regimen treatment, with IXA < 3 months from their initial treatment or will be prescribed were included in the study. The enrolled pts with RRMM who received at least one dose of IXA-lenalidomide-dexamethasone (IRd) treatment were assigned to cohort 1. The newly diagnosed multiple myeloma (NDMM) and non-myeloma pts who have received at least one dose of IXA-based regimen, and RRMM pts who have received at least one dose of non-IRd IXA-based treatment were assigned to cohort 2. The primary outcome of this analysis is to evaluate the safety profile of IXA in a Chinese patient population. The secondary outcomes are effectiveness (ORR, DOT, TTNT, PFS, OS) of IXA in RRMM patients, safety, and efficacy based on clinical / disease characteristics as defined in cohort 1 and cohort 2. The time to event outcomes was estimated by the Kaplan-Meier method for incomplete observations and all statistical analysis were performed using SAS Enterprise Guide 8.3 software. Results: As of 31 Jan 2022 (data cut-off), 114 pts (Cohort 1 (n=6); Cohort 2 (n=108)) were enrolled and considered for data analysis. Among these, 10 pts had discontinued/withdrew from the study (1 pts due to disease progression, 2 pts due to death, 7 pts for other reasons). On overall evaluation at baseline 114 pts have been treated with IXA; median age 65 yrs [range 34-89]; 59.6% male; 35.1% with ISS III disease; 26.3% with R-ISS III disease; 62.3% with Durie-Salmon stage III; 32.5% with high-risk by Stratification of Mayo mSMART guidelines; 15.8% patient received stem cell transplantation. 78.9/17.5/7.0/ 2.6% pts had received prior treatment in L1/L2/L3/other respectively, before IXA. Further, 64 %pts received a V-based regimen including VCD/VRD/VTD in first-line therapy. Route of bortezomib administration was by intravenous injection and subcutaneous injection in 21.9% and 48.2% pts respectively, with the rest unknown. At baseline evaluation, 2.6/7.9/8.8/4.4% pts had achieved sCR/CR/VGPR/PR (Table 1). At the time of this IA, median follow-up is 4.01 month, 91.2% (104/114) of pts were still on therapy and enrollment is ongoing. Median duration from the start of IXA-based treatment was 3.5 months. The median time to next treatment was 3.8 months. Treatment-emergent adverse events (TEAEs) related to IXA were 43.0% and treatment-emergent serious adverse events (SAE) related to IXA were 4.4%. TEAEs leading to treatment discontinuation (temporary and permanent) were 7.9%. TEAEs leading to discontinuation of the study were 0.9%. SAEs leading to treatment discontinuation (temporary and permanent) were 2.6%. SAEs leading to discontinuation of the study were 0.9%. TEAE of special interest were 4.4%. TEAE with Outcome of Death is 1.8% (Table 2). Conclusion: The interim analysis results show characteristics in pts receiving IXA in real-world clinical practice. The safety profile of IXA in Chinese patients is consistent with the TOURMALINE-MM1-China Continuation Study. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
wanci的应助被ooo采纳,获得10
1秒前
Misty发布了新的文献求助20
1秒前
null的应助被文献采纳,获得10
1秒前
米奇奇奇完成签到,获得积分10
1秒前
路戳戳发布了新的文献求助10
1秒前
Eylinda发布了新的文献求助10
2秒前
Hello的应助被冰_采纳,获得10
2秒前
笨笨宫苴发布了新的文献求助10
2秒前
王安之完成签到,获得积分20
3秒前
林钰凯发布了新的文献求助10
3秒前
乐池发布了新的文献求助10
3秒前
Mr.egg发布了新的文献求助10
3秒前
顺利白柏完成签到,获得积分10
3秒前
小布丁完成签到,获得积分10
3秒前
gkhsdvkb发布了新的文献求助10
3秒前
Canyon老师发布了新的文献求助10
3秒前
4秒前
4秒前
4秒前
小巧如音发布了新的文献求助10
4秒前
Lev完成签到,获得积分10
5秒前
甜蜜蘑菇完成签到,获得积分10
5秒前
谷雷努完成签到 ,获得积分10
5秒前
5秒前
无私的柠檬完成签到,获得积分10
5秒前
斯文败类的应助被Cyane采纳,获得10
5秒前
5秒前
六六发布了新的文献求助30
6秒前
yukunwang完成签到 ,获得积分10
6秒前
蓝天的应助被liuqz1209采纳,获得10
6秒前
弦弦弦完成签到,获得积分10
6秒前
6秒前
Yang发布了新的文献求助10
6秒前
6秒前
传奇3的应助被飘逸蜡烛采纳,获得10
6秒前
坚定的亦寒完成签到,获得积分10
6秒前
6秒前
6秒前
Cherry发布了新的文献求助10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8155187
求助须知:如何正确求助?哪些是违规求助? 9551559
关于积分的说明 21705535
捐赠科研通 7744381
什么是DOI,文献DOI怎么找? 3426041
关于科研通互助平台的介绍 2551144
邀请新用户注册赠送积分活动 2469770